Back to News

Three Indian CDMOs ready to seize the BIOSECURE Act opportunity

In the wake of escalating tensions between the United States and China, the Biden Administration is intensifying its strategic focus on biosecurity.

“The BIOSECURE Act and related changes are prompting several Western pharma, biotech, and other life sciences players to revisit their strategy,” Ramesh Subramanian, chief commercial officer at Aragen Life Sciences, told Bio Pharma Reporter. “We are in active discussions with several of our customers on their strategy forward so that we can be ready to meet their near-term/mid-term needs.”

Click BioPharma Reporter to read the full article.

Source: BioPharma Reporter